EPS for TMAC Resources Inc. (TMR) Expected At $0.09; Pentwater Capital Management LP Has Lowered Esperion Therapeutics (ESPR) Stake

April 17, 2018 - By Steve Bissell

Pentwater Capital Management Lp decreased Esperion Therapeutics Inc (ESPR) stake by 14% reported in 2017Q4 SEC filing. Pentwater Capital Management Lp sold 313,969 shares as Esperion Therapeutics Inc (ESPR)’s stock rose 22.41%. The Pentwater Capital Management Lp holds 1.93 million shares with $127.02 million value, down from 2.24M last quarter. Esperion Therapeutics Inc now has $2.04B valuation. The stock increased 3.45% or $2.57 during the last trading session, reaching $77.06. About 406,676 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 89.86% since April 17, 2017 and is uptrending. It has outperformed by 78.31% the S&P500.

Analysts expect TMAC Resources Inc. (TSE:TMR) to report $0.09 EPS on May, 10 after the close.They anticipate $0.12 EPS change or 400.00% from last quarter’s $-0.03 EPS. T_TMR’s profit would be $8.25M giving it 22.19 P/E if the $0.09 EPS is correct. After having $-0.14 EPS previously, TMAC Resources Inc.’s analysts see -164.29% EPS growth. The stock decreased 0.13% or $0.01 during the last trading session, reaching $7.99. About 45,983 shares traded or 29.34% up from the average. TMAC Resources Inc. (TSE:TMR) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

TMAC Resources Inc. acquires, explores for, evaluates, and develops mineral properties in Canada. The company has market cap of $732.84 million. The firm primarily explores for gold deposits. It currently has negative earnings. The Company’s principal asset is the Hope Bay Project covering an area of 1,101 square kilometers located in the Kitikmeot region of western Nunavut Territory.

Among 5 analysts covering TMAC Resources Inc (TSE:TMR), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. TMAC Resources Inc had 11 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of TMAC Resources Inc. (TSE:TMR) has “Market Perform” rating given on Friday, October 13 by BMO Capital Markets. The firm has “Speculative Outperform” rating by BMO Capital Markets given on Thursday, August 20. The rating was maintained by National Bank Canada with “Outperform” on Wednesday, July 20. RBC Capital Markets initiated the shares of TMR in report on Monday, December 19 with “Outperform” rating. As per Thursday, August 17, the company rating was downgraded by RBC Capital Markets. The rating was maintained by National Bank Canada with “Sector Perform” on Monday, August 10. The stock has “Outperform” rating by Scotia Capital on Friday, January 13.

Pentwater Capital Management Lp increased Eqt Corp (Call) stake by 130,000 shares to 900,000 valued at $51.23 million in 2017Q4. It also upped Monsanto Co (Call) stake by 16,600 shares and now owns 1.07 million shares. Time Warner Inc (Call) was raised too.

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 10 have Buy rating, 0 Sell and 8 Hold. Therefore 56% are positive. Esperion Therapeutics had 61 analyst reports since July 28, 2015 according to SRatingsIntel. Chardan Capital Markets maintained the stock with “Neutral” rating in Friday, February 26 report. As per Monday, October 26, the company rating was initiated by WallachBeth Capital. Chardan Capital Markets maintained the shares of ESPR in report on Monday, August 31 with “Sell” rating. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, January 15 report. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Buy” rating by Jefferies on Monday, March 19. As per Friday, August 7, the company rating was maintained by Chardan Capital Markets. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Neutral” rating by JP Morgan on Wednesday, February 21. On Tuesday, February 28 the stock rating was upgraded by Citigroup to “Buy”. The rating was maintained by Needham with “Buy” on Wednesday, October 18. The rating was maintained by Chardan Capital Markets on Tuesday, September 29 with “Sell”.

Investors sentiment decreased to 1.33 in 2017 Q4. Its down 0.34, from 1.67 in 2017Q3. It is negative, as 19 investors sold ESPR shares while 39 reduced holdings. 33 funds opened positions while 44 raised stakes. 22.69 million shares or 0.18% less from 22.73 million shares in 2017Q3 were reported. Partners Grp Incorporated Ag has invested 0.07% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Caisse De Depot Et Placement Du Quebec holds 0.04% or 250,000 shares. Swiss Commercial Bank reported 34,300 shares. Perceptive Advisors Ltd Llc stated it has 10,769 shares or 0.02% of all its holdings. Hall Laurie J Trustee reported 0.01% stake. Moreover, State Of Wisconsin Inv Board has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). 165,000 are owned by Iguana Management. Jpmorgan Chase & Company reported 82,261 shares stake. Parametric Portfolio Ltd Liability Corp owns 44,943 shares for 0% of their portfolio. Meeder Asset Mgmt accumulated 371 shares. First Mercantile Trust accumulated 4,233 shares or 0.05% of the stock. Moreover, Atika Cap Management Limited has 1.43% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 56,000 shares. Voya Investment Mngmt Lc reported 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Sg Americas Ltd Liability Company owns 3,023 shares. Dimensional Fund Advsr LP holds 86,676 shares or 0% of its portfolio.

Analysts await Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report earnings on May, 3. They expect $-1.56 earnings per share, up 13.33% or $0.24 from last year’s $-1.8 per share. After $-1.44 actual earnings per share reported by Esperion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 8.33% negative EPS growth.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Steve Bissell

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: